CARDIAC ARRHYTHMIAS IN HYPERTROPHIC CARDIOMYOPATHY
Abstract
Up-to-date approaches to management of atrialfibrillation and ventricular tachyarrhythmias in patients with hypertrophic cardiomyopathy are considered; the problems of sudden cardiac death prevention are discussed.
About the Authors
N. T. Vatutin
Институт неотложной и восстановительной хирургии им. В.К. Гусака; Донецкий национальный медицинский университет им. М. Горького
Russian Federation
Russian Federation
G. G. Taradin
Институт неотложной и восстановительной хирургии им. В.К. Гусака; Донецкий национальный медицинский университет им. М. Горького
Russian Federation
Russian Federation
E. V. Kartamysheva
Донецкий национальный медицинский университет им. М. Горького
Russian Federation
Russian Federation
References
1. Maron B.G., McKenna W.J., Danielson G.K. et al_ACC / ESC_clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines // J Am Coll Cardiol. 2003; 42 (9): 1687-1713.
2. Gersh B.J., Maron B.G., Bonow R.O. et al. 2011 ACCF/ AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines // J Am Coll Cardiol 2011; 58 (25): 2703-2738.
3. Elliott P.M., Anastasakis A., Borger M.A. et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: The task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC) // Eur Heart J 2014; 35: 2733-2779.
4. Беленков Ю.Н., Привалова Е.В., Каплунова В.Ю. и др. Гипертрофическая кардиомиопатия - современное состояние проблемы. Вопросы эпидемиологии и номенклатуры, генетики и патофизиологии, вариантов течения и дифференциального диагноза // Кардиология 2013; 5: 4-12.
5. Ватутин Н.Т., Тарадин Г.Г., Марон М.С. Гипертрофическая кардиомиопатия: генетические изменения, патогенез и патофизиология // Российский кардиологический журнал 2014, 5 (109): 35-42.
6. Каплунова В.Ю., Беленков Ю.Н., Привалова Е.В. и др. Вопросы этиологии, патофизиологии и вариантов течения гипертрофической кардиомиопатии. Журнал сердечная недостаточность // 2013, 14(3): 141-148.
7. Lee T.M., Chung W.K. Genetic sand hypertrophic cardiomyopathy // Curr Pediatr Rep. 2016; 4: 35-44.
8. Adabag A.S., Casey S.A., Kuskowski M.A. et al. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy // J Am Coll Cardiol 2005; 45: 697-704.
9. Adabag A.S., Maron B.J., Appelbaum E. et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy // J Amer Coll Cardiol. 2008; 51: 1369-74.
10. Целуйко В.И., Мордяшова С.В. Нарушения ритма сердца у больных гипертрофической кардиомиопатией // Международный медицинский журнал. 2008; 3: 29-33.
11. Gu S., Liu Z., Liu Z. Prevalence and related factors of arrhythmias in patients with hypertrophic cardiomyopathy // Heart 2012; 98 (suppl. 2): 248-249.
12. Wijeyeratne Y.D. Arrhythmias in hypertrophic cardiomyopathy and 2014 ESC Guidelines. // British Heart Rhythm Society. Editorial. 09.02.2015. Код доступа (активен 28.10.2016): http: //www.bhrs.com/editorial-ar-rhythmias-in-hypertrophic-cardiomyopathy.
13. MacIntyre C., Lakdawala N.K. Management of atrial fibrillation in hyperthrophic cardiomyopathy. // Circulation 2016; 133: 1901-1905.
14. Ватутин Н.Т., Тарадин Г.Г., Марон М.С., Шевелёк А. Н. Внезапная сердечная смерть у больных гипертрофической кардиомиопатией. // Кардиология. 2016; 1: 56-65.
15. Maron B.G. Contemporary insights and strategies for risk stratification and prevention of sudden death in hypertrophic cardiomyopathy. // Circulation. 2010; 121: 445-456.
16. O’Mahony C., Elliott P.M. Prevention of sudden cardiac death in hypertrophic cardiomyopathy // Heart 2014; 100: 254-260.
17. Богачев-Прокофьев А.В., Железнев С.И., Фоменко М.С., и др. Эффективность сочетанного лечения фибрилляции предсердий у пациентов с обструктивной гипертрофической кардиомиопатией. // Вестник арит-мологии 2016; 84: 12-16.
18. Olivotto I., Cecchi F., Casey S.A. et al. Impact of atrial fibrillation on the clinical course of hyperthrophic cardiomyopathy. // Circulation 2001; 104: 2517-2524.
19. Kubo T., Kitaoka H., Okawa M. et al. Clinical impact of atrial fibrillation in patients with hyperthrophic cardiomyopathy: results from Kochi RYOMA Study. // Circ J. 2009; 73: 1599-1605.
20. Thyagarajan B., Kalra A., Rajabali A. et al. Subclinical atrial fibrillation in patients with hypertrophic cardiomyopathy. // US Cardiology Review 2016; 10(2): 75-7.
21. Siontis K.C., Geske J.B., Ong K. et al. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population. // J Am Heart Assoc. 2014; 3: e001002.
22. Guttmann O.P., Rahman M.S., O’Mahony C. et al. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. // Heart 2014; 100: 465-472.
23. Olshansky B., Heller E.N., Mitchell L.B. et al. Are transthoracic echocardiographic parameters associated with atrial fibrillation recurrence or stroke? Results from the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study. // J Am Coll Cardiol. 2005; 45 (12): 2026-2033.
24. Yang H., Woo A., Monakier D. et al. Enlarged left atrial volume in hypertrophic cardiomyopathy: a marker for disease severity. // J Am Soc Echocardiogr. 2005; 18: 1074-1082.
25. Богданов Д.В. Сферическое ремоделирование левого предсердия при гипертрофической необструктив-ной кардиомиопатии. // Кардиология 2012; 4: 49-52.
26. Girasis C., Vassilikos V., Efthimiadis G.K. et al. Patients with hypertrophic cardiomyopathy at risk for paroxysmal atrial fibrillation: advanced echocardiographic evaluation of the left atrium combined with noninvasive P-wave analysis. // Eur Heart J Cardiovasc Imaging 2013; 14: 425-434.
27. Yamaji K., Fujimoto S., Yutani C. et al. Does the progression of myocardial fibrosis lead to atrial fibrillation in patients with hypertrophic cardiomyopathy? // Cardiovasc Pathol 2001; 10: 297-303.
28. Kumar K.R., Mandleywala S.N., Link M.S. Atrial and ventricular arrhythmias in hypertrophic cardiomyopathy. // Card Electrophysiol Clin. 2015; 7 (2): 173-186.
29. Pujadas S., Vidal-Perez R., Hidalgo A. et al. Correlation between myocardial fibrosis and the occurrence of atrial fibrillation in hypertrophic cardiomyopathy: a cardiac magnetic resonance imaging study. // Eur J Radiol 2010; 75: e88-91.
30. Kubo T., Kitaoka H., Okawa M. et al. Serum cardiac troponin I is related to increased left ventricular wall thickness, left ventricular dysfunction, and male gender in hypertrophic cardiomyopathy. // Clin Cardiol. 2010; 33: E1-E7.
31. Moreno V., Hernandez-Romero D., Vilchez J.A. et al. Serum levels of high-sensitivity T: a novel marker for cardiac remodeling in hypertrophic cardiomyopathy. // J Card Fail. 2010; 16: 950-956.
32. Nakamura S., Takano H., Matsuda J. et al. Prognostic values of highly sensitive cardiac troponin T and B-type natriuretic peptide for clinical features in hypertrophic obstructive cardiomyopathy: a cross-sectional study. // BMJ Open 2014; 4: e005968.
33. Maron M.S., Olivotto I., Betocchi S. et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. // N Engl J Med 2003; 348 (4): 295-303.
34. Autore C., Bernabo P., Barillà C.S. et al. The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms. // J Am Coll Cardiol. 2005; 45 (7): 1076-1080.
35. Park K.M., Im S.I., Kim E.K. et al. Atrial fibrillation in hypertrophic cardiomyopathy: is the extent of septal hypertrophy important? // PLoS One 2016; 11 (6): e0156410.
36. Holmqvist F., Platonov P.G., Carlson J. et al. Variable interatrial conduction illustrated in a hypertrophic cardiomyopathy population. // Ann Noninvasive Electrocardiol. 2007; 12: 227-36.
37. Shigematsu Y., Hamada M., Nagai T. et al. Risk for atrial fibrillation in patients with hypertrophic cardiomyopathy: association with insulin resistance // J Cardiol. 2011; 58 (1): 18-25.
38. Guttmann O.P., Pavlou M., O’Mahony C. et al. Hypertrophic Cardiomyopathy Outcomes Investigators. Prediction of thromboembolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA). // Eur J Heart Fail 2015; 17: 837-845.
39. Granger C.B., Alexander J.H., McMurray J.J. et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. // N Engl J Med 2011; 365: 981-992.
40. Kirchhof P., Benussi S., Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). // Eur J Cardiothorac Surg. 2016 Sep 23. pii: ezw313.
41. Ammirati E., Contri R., Coppini R. et al. Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. // Eur J Heart Fail 2016; 18(9): 1106-18.
42. Габрусенко С.А., Сафрыгина Ю.В., Наумов В.Г., Беленков Ю.Н. Современные подходы к лечению больных гипертрофической кардиомиопатией. // Лечащий врач 2004; 2: 32-37.
43. Robinson K., Frenneaux M.P., Stockins B. et al. Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. // J Am Coll Cardiol 1990; 15: 1279-1285.
44. Бокерия Л.А. Гипертрофическая обструктивная кардиомиопатия. // Анналы хирургии 2013; 5: 5-14.
45. Sherrid M.V, Barac I., McKenna W.J. et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. // J Am Coll Cardiol. 2005; 45: 1251-1258.
46. January C.T., Wann L.S., Alpert J.S. et al. ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. // J Am Coll Cardiol 2014; 64: 2246-2280.
47. Contreras-Valdes F.M., Buxton A.E., Josephson M.E., Anter E. Atrial fibrillation ablation in patients with hypertrophic cardiomyopathy long-term outcomes and clinical predictors. // J Am Coll Cardiol 2015; 65 (14): 1485-1487.
48. Di Donna P., Olivotto I., Delcrè S.D. et al. Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: impact of age, atrial remodelling, and disease progression. // Europace 2010; 12: 347-355.
49. Gaita F., Di Donna P., Olivotto I. Usefulness and safety of transcatheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy. // Am J Cardiol 2007; 99: 1575-1581.
50. Ozawa K., Funabashi N., Takaoka H. et al. Various morphological-types of all and fragmented ventricular premature beats on a 12-lead Holter-ECG had positive-relationship with occurrence of LV fibrosis on CT in HCM subjects. // Int J Cardiol. 2014; 171 (3): 450-456.
51. Cha Y.M., Gersh B.J., Maron B.J. et al. Electrophysi-ologic manifestations of ventricular tachyarrhythmias provoking appropriate defibrillator interventions in high-risk patients with hypertrophic cardiomyopathy. // J Cardiovasc Electrophysiol 2007; 18: 1-5.
52. O’Mahony C., Lambiase P.D., Rahman S.M. et al. The relation of ventricular arrhythmia electrophysiological characteristics to cardiac phenotype and circadian patterns in hypertrophic cardiomyopathy. // Europace 2012; 14 (5): 724-733.
53. Priori S.G., Blomström-Lundqvist C., Mazzanti A. et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). // Eur Heart J. 2015; 36 (41): 2793-867.
54. Giles K., Green M.S. Workup and management of patients with frequent premature ventricular contractions. // Can J Cardiol. 2013; 29 (11): 1512-1515.
55. Бокерия О.Л., Ахобеков А. А. Желудочковая экстра-систолия. // Анналы аритмологии 2015; 12 (1): 16-24.
56. Cantillon D.J. Evaluation and management of premature ventricular complexes. // Clev Clin J Med 2013; 80 (6): 377-387.
57. Jackson B.L., Adin D.B., Lehmkuhl L.B. Effect of atenolol on heart rate, arrhythmias, blood pressure, and dynamic left ventricular outflow tract obstruction in cats with subclinical hypertrophic cardiomyopathy. // J Vet Cardiol. 2015; 17 Suppl 1: 296-305.
58. Hamada M., Ikeda S., Shigematsu Y. Advances in medical treatment of hypertrophic cardiomyopathy. // J Cardiol. 2014; 64 (1): 1-10.
59. Целуйко В.И., Белостоцкая Е.А. Внезапная коронарная смерть при гипертрофической кардиомиопа-тии. // Внутренняя медицина 2009; 1-2: 13-14.
60. Monserrat L., Elliott P.M., Gimeno J.R. et al. Non-sus-tained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. // J Am Coll Cardiol 2003; 42: 873-879.
61. Gimeno J.R., Tomé-Esteban M., Lofiego C. et al. Exercise-induced ventricular arrhythmias and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy. // Eur Heart J 2009; 30: 2599-2605.
62. Katritsis D.G., Zareba W., Camm A.J. Non-sustained ventricular tachycardia. // J Am CollCardiol 2012; 60 (20): 1993-2004.
63. Fananapazir L., Epstein S.E. Hemodynamic and elec-trophysiologic evaluation of patients with hypertrophic cardiomyopathy surviving cardiac arrest. // Am J Cardiol 1991; 67: 280-287.
64. Бокерия Л.А., Берсенёва М.И., Маленков Д.А. Аритмогенные осложнения гипертрофической карди-омиопатии. // Анналы аритмологии 2010; 3: 62-69.
65. Shah D.K., Schaff H.V., Abel M.D., Gersh B.J. Ventricular tachycardia in hypertrophic cardiomyopathy with apical aneurysm. // Ann Thorac Surg 2011; 91: 1263-1265.
66. Kobayashi K., Ohata T., Ueda H., Miyamoto K. Recurrent sustained ventricular tachycardia, hypertrophic cardiomyopathy, and apical aneurysm: electro-anatomic map-guided surgical ablation and left ventricular restoration. // J Thorac Cardiovasc Surg. 2013; 146 (4): 983-985.
67. Di Salvo G., Pacileo G., Limongelli G. et al. Non sustained ventricular tachycardia in hypertrophic cardiomyopathy and new ultrasonic derived parameters. // J Am Soc Echocardiogr. 2010; 23 (6): 581-590.
68. Correia E., Rodrigues B., Santos L.F. et al. Longitudinal left ventricular strain in hypertrophic cardiomyopathy: correlation with non-sustained ventricular tachycardia. // Echocardiography 2011; 28 (7): 709-714.
69. Fujita T., Konno T., Yokawa J. et al. Increased extent of myocardial fibrosis in genotyped hypertrophic cardiomyopathy with ventricular tachyarrhythmias. // J Cardiol. 2015; 66 (1): 63-68.
70. Puntmann V.O., Yap Y.G., McKenna W., Camm A.J. Significance of maximal and regional left ventricular wall thickness in association with arrhythmic events in patients with hypertrophic cardiomyopathy. // Circ J 2010; 74: 531537.
71. Oka K., Tsujino T., Nakao S. et al. Symptomatic ventricular tachyarrhythmia is associated with delayed gadolinium enhancement in cardiac magnetic resonance imaging and with elevated plasma brain natriuretic peptide level in hypertrophic cardiomyopathy. // J Cardiol 2008; 52: 146-153.
72. Kwon D.H., Setser R.M., Popovic Z.B. et al. Association of myocardial fibrosis, electrocardiography and ventricular tachyarrhythmia in hypertrophic cardiomyopathy: a delayed contrast enhanced MRI study. // Int J Cardiovasc Imaging 2008; 24: 617-625.
73. Chan R.H., Maron B.J., Olivotto I. et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. // Circulation 2014; 130: 484-495.
74. Kwon D.H., Smedira N.G., Rodriguez E.R. et al. Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy: correlation with histopathology and prevalence of ventricular tachycardia. // J Am Coll Cardiol 2009; 54: 242-249.
75. Amano Y., Kitamura M., Tachi M. et al. Delayed enhancement magnetic resonance imaging in hypertrophic cardiomyopathy with basal septal hypertrophy and preserved ejection fraction: relationship with ventricular tachyarrhythmia. // J Comput Assist Tomogr 2014; 38: 67-71.
76. Appelbaum E., Maron B.J., Adabag S. et al. Intermediate-signal-intensity late gadolinium enhancement predicts ventricular tachyarrhythmias in patients with hypertrophic cardiomyopathy. // Circ Cardiovasc Imaging 2012; 5: 78-85.
77. Kawasaki T., Sakai C., Harimoto K. et al. Holter monitoring and long-term prognosis in hypertrophic cardiomyopathy. // Cardiology 2012; 122: 44-54.
78. Yokoshiki H., Mitsuyama H., Watanabe M. et al. Suppression of ventricular fibrillation by electrical modification of the Purkinje system in hypertrophic cardiomyopathy. // Heart Vessels. 2014; 29 (5): 709-717.
79. Maron B.J., Spirito P., Shen W.K. et al. Implantable cardioverter-defibrillator sand prevention of sudden cardiac death in hypertrophic cardiomyopathy. // JAMA 2007; 298: 405-412.
80. O’Mahony C., Jichi F., Pavlou M. et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCMrisk-SCD). // Eur Heart J 2014; 35: 2010-2020.
81. O’Mahony C., Elliott P., McKenna W. Sudden cardiac death in hypertrophic cardiomyopathy // Circ Arrhythm Electrophysiol 2013; 6: 443-451.
82. Schinkel A.F., Vriesendorp P.A., Sijbrands E.J. et al. Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: Systematic review and meta-analysis. // Circ Heart Fail 2012; 5: 552-559.
83. Pasqualucci D., Fornaro A., Castelli G. et al. Clinical spectrum, therapeutic options, and outcome of advanced heart failure in hypertrophic cardiomyopathy // Circ Heart Fail 2015; 8: 1014-1021.
84. Vriesendorp P.A., Schinkel A.F., Liebregts M. et al. Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy. // Circ Arrhythm Electrophysiol 2015; 8: 829-835.
85. Peterson P.N., Daugherty S.L., Wang Y. et al. Gender differences in procedure-related adverse events in patients receiving implantable cardioverter-defibrillator therapy. // Circulation 2009; 119: 1078-1084.
86. Weinstock J., Bader Y.H., Maron M.S. et al. Subcutaneous implantable cardioverter defibrillator in patients with hypertrophic cardiomyopathy: an initial experience. // J Am Heart Assoc. 2016; 5: e00248.
87. Lamichhane M., Safadi A., Surapaneni P. et al. Use of the wearable cardioverter defibrillator in high-risk populations. // Curr Cardiol Rep. 2016; 18 (8): 78.
Review
For citations:
Vatutin N.T., Taradin G.G., Kartamysheva E.V. CARDIAC ARRHYTHMIAS IN HYPERTROPHIC CARDIOMYOPATHY. Journal of Arrhythmology. 2016;(86):43-50. (In Russ.)
Views:
258
Email this article 